Global Biolayer Interferometry (BLI) Market Growth (Status and Outlook) 2025-2031

The global Biolayer Interferometry (BLI) market size is predicted to grow from US$ 382 million in 2025 to US$ 666 million in 2031; it is expected to grow at a CAGR of 9.7% from 2025 to 2031.

Biolayer Interferometry (BLI) is a label-free optical technique for measuring biomolecular interactions in real-time. It analyzes the interference pattern of white light reflected from an immobilized protein layer on the biosensor tip and an internal reference layer. Only molecules binding to or dissociating from the biosensor can shift the interference pattern, making BLI unique and ideal for protein binding, quantitation, affinity, and kinetics in crude samples. Bio-Layer Interferometry measures biomolecular interactions by analyzing interference patterns of white light reflected from the surface of a biosensor tip. In BLI experiment, one molecule is immobilized to a biosensor and binding to a second molecule is measured. The molecules that bind or dissociate themselves from the biosensor causes a shift in the interference pattern that is measured in real-time. The unbound molecules, variations in the refractive index of the surrounding medium or flow rate, however, do not affect the interference. This unique feature of BLI technology therefore allows measuring crude samples to determine the kinetics and affinity of molecular interactions. Anotheradvantage of BLI is that the number of sensors can be scaled up easily without making the system more error-prone or complex. Theoretically, there is no need to regenerate single sensors, because immobilizing an equal amount of ligand on additional sensors can easily create duplicates of the surface.

The Biolayer Interferometry (BLI) market has been expanding rapidly due to its increasing use in a wide range of applications such as drug discovery, biotechnology, diagnostics, and life sciences research. BLI is a powerful, label-free, and real-time optical biosensing technique that is widely used for studying molecular interactions. Here are the most prominent market trends for BLI:

BLI is becoming an essential tool in drug discovery and biopharmaceutical development. The technique is crucial for assessing the interactions of small molecules, antibodies, peptides, and other therapeutics with biological targets. BLI is particularly useful in the screening of drug candidates, kinetic analysis, and the characterization of biologics like monoclonal antibodies and biosimilars.

With increased emphasis on biologics, biomolecular interactions, and antibody-drug conjugates (ADCs), the demand for BLI instruments is surging in pharmaceutical research labs, contract research organizations (CROs), and biotechnology companies.

One of the key advantages of BLI is its ability to monitor biomolecular interactions in real-time without the need for labels like fluorescence or radioactivity. This is especially important for applications in kinetic studies, where changes in molecular binding or dissociation are observed in real time. The technology’s label-free nature also makes it a more cost-effective and sustainable option compared to traditional assays.

Real-time monitoring allows for high-throughput analysis, which is essential for large-scale drug screening campaigns and biomarker discovery.

The BLI market is benefiting from its integration with high-throughput screening (HTS) platforms. The combination of label-free detection and the ability to screen large numbers of samples in a short time is making BLI a popular choice in drug development and compound screening. This integration is especially useful for accelerating the early stages of drug discovery.

Many manufacturers are developing BLI systems that can be easily integrated into existing HTS workflows, improving efficiency and throughput while providing high-quality interaction data.

LPI (LP Information)' newest research report, the “Biolayer Interferometry (BLI) Industry Forecast” looks at past sales and reviews total world Biolayer Interferometry (BLI) sales in 2024, providing a comprehensive analysis by region and market sector of projected Biolayer Interferometry (BLI) sales for 2025 through 2031. With Biolayer Interferometry (BLI) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biolayer Interferometry (BLI) industry.

This Insight Report provides a comprehensive analysis of the global Biolayer Interferometry (BLI) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biolayer Interferometry (BLI) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biolayer Interferometry (BLI) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biolayer Interferometry (BLI) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biolayer Interferometry (BLI).

This report presents a comprehensive overview, market shares, and growth opportunities of Biolayer Interferometry (BLI) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Affinity and Kinetic Analysis
Drug and Antibody Screening
Drug and Antibody Discovery
Protein Quantification
Others

Segmentation by Application:
Pharmaceutical Industry
Diagnostics
Biotechnology
Scientific Research
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ichor Life Sciences, Inc
Creative BioMart
GenScript
ROCKLAND IMMUNOCHEMICALS, INC
BPS Bioscience, Inc
Creative Proteomics
Creative Biostructure
Profacgen
Creative Biolabs
Biocult
KMD Bioscience Co., Ltd

Please note: The report will take approximately 2 business days to prepare and deliver.